ON-DEMAND WEBINAR

Trends in Clinical Trial Planning

TERESA FISHBURNE
Global Practice Lead, Clinical & Regulatory Consulting Head of the Centre of Medicines Research (CMR)
Clarivate
SAMANTHA CHESNEY
Product Manager, Clinical
Clarivate

Across all trial phases (I-III), 53% of trial protocols need to be amended after initiation. These amendments mean delays in critical timelines that can quickly cause you to fall behind in the race to beat the competition. Each day a drug is delayed from the market, sponsors lose up to $8m. So how can you increase the odds of designing your trial correctly the first time?

In this webinar, we look at tens of thousands of trial designs over the past decade – protocols, site identification, biomarker selection, and more – to uncover answers to questions that will position your clinical trial for success from day one:

  • How have trials evolved over time?
  • What can we learn from changes in trial design trends?
  • Has trial design changed over time to align with the need for simplification and greater accessibility to certain populations?
  • How will COVID-19 impact trial design in the coming years